HMGA2 binding to supercoiled DNA structures may interfere with the Topo-I/DNA complex formation in a concentration-dependent manner [103], highlighting that HMGA2 abundance in individual CRC tumors may determine sensitivity to Topo I and II inhibitors. The gene discussed is HMGA2; the disease is colorectal carcinoma.